IMV101 treatment

Phase 2Biologic

SSuzhou Immunofoco Biotechnology Co., Ltd

IMV101 treatment is one of 57 biologic programs targeting Relapsed/Refractory Multiple Myeloma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed/refractory Multiple MyelomaRecruiting

LymphomaRecruiting

Relapsed/refractory Multiple MyelomaPhase 1

Recruiting

LymphomaPhase 2

Recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zofran

Novartis

Preclinical

2 2

Norvir

AbbVie

Preclinical

1 3

Cabenuva

GSK

Preclinical

1 4

IMV101 treatment

SSuzhou Immunofoco Biotechnology Co., Ltd

Phase 2

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—10

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Lymphoma

NCT07376642

Q2 2028

Phase 1Recruiting

Relapsed/refractory Multiple Myeloma

NCT07493135

Clinical

Trials by Indication[1]

Lymphoma1 trial

A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Recruiting·SSuzhou Immunofoco Biotechnology Co., Ltd·Phase 1/2·NCT07376642·30 enrolled

Relapsed/Refractory Multiple Myeloma1 trial

A Single-Arm, Open-Label Early-Phase Clinical Study of IMV102 Injection in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting·SSuzhou Immunofoco Biotechnology Co., Ltd·Phase 1·NCT07493135·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IMV101 treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IMV101 treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IMV101 treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou Immunofoco Biotechnology Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SSuzhou Immunofoco Biotechnology Co., Ltd

IMV101 treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Trials by Indication[1]

Lymphoma1 trial

Relapsed/Refractory Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News